Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis-Reference-Cited by-同舟云学术

Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis

Published:2018-03-02 Issue:5 Volume:81 Page:809-814
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Takasaki Kazuki^ORCID,Miyamoto Morikazu^ORCID,Takano Masashi^ORCID,Soyama Hiroaki^ORCID,Aoyama Tadashi^ORCID,Matsuura Hiroko^ORCID,Kato Kento^ORCID,Sakamoto Takahiro^ORCID,Kuwahara Mika^ORCID,Iwahashi Hideki^ORCID,Ishibashi Hiroki^ORCID,Yoshikawa Tomoyuki^ORCID,Furuya Kenichi^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-018-3552-5/fulltext.html

Reference18 articles.

1. Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, DeSimone CP, Ueland FR, van Nagell JR, Seamon LG (2012) Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol 120:612–618. https://doi.org/10.1097/AOG.0b013e318264f794

2. Pujade-Lauraine E, Alexandre J (2011) Update of randomized trials in recurrent disease. Ann Oncol 22:viii61–viii64. https://doi.org/10.1093/annonc/mdr518

3. Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, Wang Y, Scribner DR Jr, Marciniack M, Naumann RW, Secord AA (2007) Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25:2811–2818. https://doi.org/10.1200/JCO.2006.09.6735

4. Coleman RL, Monk BJ, Sood AK, Herzog TJ (2013) Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 10:211–224. https://doi.org/10.1038/nrclinonc.2013.5

5. Naumann RW, Coleman RL (2011) Management strategies for recurrent platinum-resistant ovarian cancer. Drugs 71:1397–1412. https://doi.org/10.2165/11591720-000000000-00000

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: a retrospective analysis;BMC Cancer;2022-02-16

2. Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer;International Journal of Clinical Oncology;2022-01-05

3. Chemotherapeutic Protocols for the Treatment of Gynecological Cancer;Chemotherapy Protocols and Infusion Sequence;2022

4. Efficacy of Gemcitabine and Bevacizumab Combination Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: A Retrospective Analysis;Journal of St. Marianna University;2021

5. A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma;Gynecologic Oncology;2020-06